Ajay Royan, a director at Fractyl Health, Inc. (NASDAQ: GUTS), has increased his direct stake in the company through a recent open market transaction. On June 12, 2026, Royan purchased 23,000 shares of common stock at a price of $0.852 per share. The total value of this acquisition stands at $19,596. Following this transaction, Royan's direct ownership of Fractyl Health common stock now totals 40,901 shares. The transaction was formally disclosed in a Form 4 filing submitted to the Securities and Exchange Commission on June 15, 2026.
Recent market performance for GUTS has shown volatility. The stock has appreciated by 26.87% over the past week, yet it remains down 62% over the last six months. According to InvestingPro analysis, GUTS currently trades above its Fair Value. Investors seeking deeper insights can access 10 additional ProTips and comprehensive analysis through the platform’s Pro Research Report, available for GUTS and 1,400+ other US stocks. The stock closed at $0.850 on the day of the report, with no change, and traded at $0.86 in after-hours activity, representing a 0.66% increase.
Mr. Royan's indirect holdings through investment entities are substantial. He holds indirect beneficial ownership of 5,160,301 shares through Mithril LP. Mithril GP LP, of which Mr. Royan is an authorized person and a member of the investment committee, serves as the general partner of Mithril LP. He disclaims beneficial ownership of these securities except to the extent of his pecuniary interest. Furthermore, Mr. Royan indirectly holds 1,251,900 shares through Mithril II LP. He is the sole managing member of Mithril II UGP LLC, which is the general partner of Mithril II GP LP, the general partner of Mithril II LP. Mr. Royan is also a member of the investment committee of Mithril II GP LP. He disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Fractyl Health recently reported its first-quarter 2026 earnings, delivering an earnings per share (EPS) of -$0.06. This result significantly surpassed the analysts’ forecast of -$0.25. Despite reporting zero revenue, this earnings surprise reflects the company’s strategic cost management and promising clinical trial advancements. Fractyl Health also announced results from its REVEAL-1 study, which showed that participants maintained approximately 78% of the weight they lost through GLP-1 medications one year after discontinuing the drugs and undergoing a single Revita procedure. The study involved 22 individuals who had lost an average of 24% of their total body weight while on GLP-1 therapy.
In leadership developments, Fractyl Health appointed Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy. Zumdahl brings experience from his previous role as Vice President of Global Health Economics, Market Access, and Government Affairs at Inari Medical. His expertise is expected to guide Fractyl Health’s market access and commercial strategies. These developments highlight Fractyl Health’s ongoing efforts to strengthen its market position and advance its clinical programs.